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Recent studies point out the link between altered mitochondrial
metabolism and cancer, and detailed understanding of mitochon-
drial metabolism requires real-time detection of its metabolites.
Employing heteronuclear 2D NMR spectroscopy and 13C3-pyruvate,
we propose in-organelle metabolomics that allows for the moni-
toring of mitochondrial metabolic changes in real time. The ap-
proach identified acetyl phosphate from human mitochondria,
whose production has been largely neglected in eukaryotic metab-
olism since its first description about 70 years ago in bacteria. The
kinetic profile of acetyl phosphate formation was biphasic, and its
transient nature suggested its role as a metabolic intermediate.
The method also allowed for the estimation of pyruvate dehydro-
genase (PDH) enzyme activity through monitoring of the acetyl-
CoA formation, independent of competing cytosolic metabolism.
The results confirmed the positive regulation of mitochondrial PDH
activity by p53, a well-known tumor suppressor. Our approach can
easily be applied to other organelle-specific metabolic studies.
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Mitochondria are metabolic organelles that carry out fun-damental functions of eukaryotic life. With the recognition
of metabolic perturbations as hallmark characteristics of cancers
(1, 2), mitochondrial metabolism has been implicated in tu-
morigenesis (3). As metabolism is essentially concerned with flux
or time-dependent metabolite changes, mitochondrial metabo-
lism is best studied by real-time detection of the metabolites
using live (functional) mitochondria. However, most of the mi-
tochondrial metabolic studies have used cell or mitochondrial
lysates and measured metabolites at a fixed time point (4).
Current approaches to metabolic flux measurement include
complicated isotope pattern analysis or mathematical modeling
(5), but they are indirect and require mitochondrial sample de-
struction. Although real-time metabolic measurements are pos-
sible with 13C-hyperpolarized NMR (6) and one-dimensional 13C
NMR spectroscopy with isolated mitochondria (7), these methods
suffer from extreme hardware requirements and disappointingly
low sensitivity with signal overlap, respectively. Therefore, a sim-
ple and efficient technique to measure real-time metabolic
activities from live mitochondria is highly desired.
Pyruvate is arguably the most important carbon source for the
tricarboxylic acid (TCA) cycle, a characteristic mitochondrial
metabolism. Pyruvate is converted to acetyl-CoA through pyru-
vate dehydrogenase (PDH), and the latter is condensed with
oxaloacetate to form citrate, starting the first step of the TCA
cycle. Acetyl-CoA is also a central metabolite in several metab-
olisms, such as fatty acid synthesis in cytosol and epigenetic
modification in nuclei. Enzymes in mitochondrial pyruvate-
related pathways, such as PDH and TCA cycle enzymes, have
been importantly implicated in tumorigenesis (8, 9). Therefore,
studying mitochondrial pyruvate metabolism with a real-time
approach may lead to previously unseen metabolic activities in-
volved in cancer-related mitochondrial metabolism.
Previously, we introduced in-cell live 2D NMR metabolomics
for real-time metabolomic study at the whole-cell level (10).
Here, carrying the concept to a higher tier for an organelle level,
we sought to investigate the pyruvate metabolism of live mito-
chondria in real time using 2D in-organelle NMR metabolomics.
Results and Discussion
Integrity of Live Mitochondrial Samples. To implement the ap-
proach, we prepared pure mitochondria from a human colon
cancer cell line (HCT116) with virtually no contamination from
cytosol (Fig. 1A). HSP60, a mitochondrial marker, and GAPDH,
a cytosolic marker, were shown to be absent in cytosolic and
mitochondrial preparations, respectively. The absence of cyto-
solic contamination was further confirmed using NMR spec-
troscopy (see NMR Experiments on Live Mitochondria and the
Identification of Acetyl Phosphate). We assured the physical and
functional integrities of the prepared mitochondria, which can
significantly affect the results, by using several test procedures.
Significance
We introduce an in-organelle live NMR metabolomics approach
that allows for real-time metabolic monitoring of live human
mitochondria. The approach also features more than an order
of magnitude higher sensitivity and much less overlap than
conventional methods. The real-time monitoring capability
identified acetyl phosphate in human mitochondria and showed
its biphasic kinetic profile typical of a reaction intermediate. The
method also allowed for estimation of pyruvate dehydrogenase
enzyme activity in live mitochondria according to p53 status, in-
dependent of competing cytosolic metabolism. Our approach
should be very useful in studies on mitochondrial-specific contri-
butions to cancer metabolism, and can be straightforwardly ex-
tended to studies on other diseases with altered mitochon-
drial metabolism.
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First, the physical integrity of mitochondria was confirmed by
observing intact mitochondria under an electron microscope
(Fig. 1B). Second, the metabolic functionality of the mitochon-
dria sampled from an NMR tube before, during, and after the
NMR experiment was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay that
depends on mitochondrial redox enzymes (11). The results
showed that the mitochondrial activities did not change much
over the period of 80 min, the maximum decrease being only
about 10% (Fig. 1C). Third, the oxygen consumption of the
mitochondria was measured using the MitoXpress probe (Fig.
1D). The results showed that the oxygen in the mitochondrial
sample was consumed over time in a mitochondrial amount-
dependent manner up to 100 min. Overall, these results confirmed
that the prepared mitochondria were metabolically functional and
an appropriate system for real-time metabolomic assessment of
live mitochondria.
NMR Experiments on Live Mitochondria and the Identification of
Acetyl Phosphate. For actual NMR experiments, the mitochon-
drial preparations were directly placed into a 5-mm Shigemi
NMR tube with 13C3-labeled pyruvate (3 mM), and a total of
eight 1H-detected 2D heteronuclear single-quantum coherence
(HSQC) NMR spectra were obtained (∼5 min each; see Mate-
rials and Methods). This very short time resolution was possible
thanks to more than an order of magnitude higher sensitivity
(32× theoretical, excluding relaxation) of 1H-detected HSQC
than the previous 13C-based 1D NMR spectroscopy approach for
isolated mitochondria (7). The obtained spectra featured time-
dependent peak changes for metabolites produced from pyru-
vate (Fig. 2A), confirming the functional mitochondrial activity.
In comparison, none of these metabolites were observed without
the addition of 13C3-pyruvate (Fig. S1). The NMR data also
allowed for the assurance of the absence of mitochondrial
membrane leakage and cytosolic contamination. We performed
the same NMR experiment with UK5099, a specific inhibitor of
mitochondrial pyruvate carrier that blocks the transport of py-
ruvate across the mitochondrial membrane (12). UK5099 treat-
ment blocked the generation of all of the observed metabolites as
well as the consumption of pyruvate (Fig. 2B). Mitochondrial
enzymes released from ruptured mitochondria or contaminating
cytosolic enzymes would not be inhibited by the pyruvate
transport inhibitor. Therefore, all of the observed metabolites
in the original experiment must have been produced by mito-
chondrial enzymes in intact mitochondria. Most of the peaks on
the spectra could be readily assigned based on the biochemical
pathways for pyruvate metabolism and the chemical shifts of the
standard compounds (Fig. 2A and Table S1). These metabolites
Fig. 1. Integrity and metabolic functionalities of live mitochondrial prepa-
rations. (A) Western blot for mitochondrial and cytosolic preparations. Mi-
tochondrial marker (HSP60) and cytosolic marker (GAPDH) were probed in
mitochondrial (Mito), whole-cell (Whole), and cytosolic (Cyto) preparations.
(B) Transmission electron micrograph of isolated mitochondria. (C) MTT as-
say for mitochondrial samples. The mitochondria were incubated for the
indicated periods in an NMR tube as in a real live NMR measurement, after
which the MTT assay was performed. (D) Oxygen consumption of the mi-
tochondrial samples obtained with the MitoXpress dye. Mitochondrial con-
centrations (as mitochondrial proteins): 0.05 mg/mL (black), 0.25 mg/mL
(red), and 1 mg/mL (blue). AFU, arbitrary fluorescence unit.
Fig. 2. HSQC spectra on live mitochondria and the identification of acetyl
phosphate. (A) Overlaid spectra taken at 5 min (black) and 40 min (red) after
the addition of 13C3-pyruvate. (B) 2D HSQC spectrum of mitochondrial
preparation at 40 min after the addition of 13C3-pyruvate and UK5099
(3 mM). For A and B, mitochondrial samples corresponding to about 400 μg
of mitochondrial protein were used. The numbers and symbols indicate
assigned metabolites for A and B: 1, pyruvate; 2, acetate; 3, glutamate; 4,
succinate; 5, citrate; 6, acetyl phosphate (tentative); 7, glutamine; T, the
tautomer peak of pyruvate; M1 and M2, putative natural abundance mito-
chondrial peaks; U, unidentified peak; and D, DMSO (see Table S1). (C) 2D
decoupled HMBC spectra for acetyl phosphate standard (STD) (Left), and a
mitochondrial extract (Mito) (Right) (red boxes: 1H = 2.09 ppm, 13C =
175.2 ppm). (D) Multiple reaction monitoring detection of acetyl phosphate
from a mitochondrial extract (Mito) (Top), and acetyl phosphate standard
(STD) (Bottom) using LC-MS/MS. Red in Top indicates 13C isotopes. (E) High-
resolution 2D HSQC spectrum of mitochondrial samples with nonuniform
sampling. The red box indicates the carbon–carbon J-splitting (57 Hz) of the
methyl group of acetyl phosphate (1H = 2.09 ppm, 13C = 24.96 ppm).








represent those formed before, during, and after the TCA cycle
that can serve as specific probe metabolites for various metabolic
nodes in mitochondria. Additionally, a peak at (1H = 2.09 ppm,
13C = 24.96 ppm) (peak 6 in Fig. 2A) was tentatively assigned as
acetyl phosphate. Its formation from pyruvate has not been
reported in human mitochondria, with reports only in bacteria
(13). Given the well-known differences between bacterial and
human metabolism, we pursued further confirmation of its
identity. As we observed only one H–C correlation of the two
carbon atoms of acetyl phosphate, we separately obtained the
heteronuclear multiple-bond correlation (HMBC) spectrum for
the other H–C–CO correlation. For this, much more mito-
chondrial extract was prepared separately, because the metabo-
lite turned out to be quite labile (see Biphasic Kinetic Profile of
Acetyl Phosphate Metabolism) and HMBC is less sensitive than
HSQC. The H–C–CO correlation appeared exactly at the
chemical shift of the standard compound (Fig. 2C). Further
proof of the presence of acetyl phosphate came from the mass
spectrometric analysis of the lysate sample, which showed the
characteristic MS/MS peak by the loss of H2PO3 from the acetyl
phosphate molecular ion (Fig. 2D). The increase in the m/z value
of the molecular ion compared with the database value (from m/z
139 to 141) showed its formation from the added 13C3-pyruvate.
This was also confirmed by JC–CO splitting (57 Hz) of the methyl
group in the high-resolution nonuniformly sampled HSQC (Fig.
2E) (14). Therefore, the NMR and mass spectrometry results
prove the synthesis of acetyl phosphate from pyruvate in human
mitochondria. It is also worth noting that the discovery of
pyruvate-to-acetyl phosphate conversion in bacteria (15, 16) was
a milestone for the later discoveries of CoA and acetyl-CoA in
eukaryotes (17, 18), which resulted in two Nobel prizes to Lipmann
(1953) and Lynen (1964). Lipmann’s work showed that acetyl
phosphate is an intermediate for the phosphorylation of adenylate
by pyruvate dehydrogenation in both aerobic and anaerobic
conditions with bacterial lysates. However, as acetyl-CoA was
considered the primary carrier of a high-energy acetyl group, the
presence and roles of acetyl phosphate in animals have been
largely neglected for more than 70 years, with very few studies
reporting its formation from citrate in the 1960s (19). In those
studies, it was suggested that acetyl phosphate might be involved
in acetylation and ketone body formation through an acetyl-CoA
intermediate in the absence of ATP. Our identification and these
previous studies may point to a previously uncharacterized meta-
bolic pathway in human mitochondria, possibly involved in phos-
phorylation or acetylation.
Biphasic Kinetic Profile of Acetyl Phosphate Metabolism. As the
metabolism of acetyl phosphate in human mitochondria has not
been established, we took advantage of the real-time monitoring
of our approach and followed the time course of its formation.
Very interestingly, acetyl phosphate exhibited a biphasic time
profile, with a decrease in its level after an initial rapid increase
for about 15 min (Fig. 3A). In addition, it could not be detected
in the mitochondrial lysate obtained after a long incubation time
(∼80 min), suggesting its rather rapid degradation (Fig. 3B). This
easy degradability and relatively low concentration may explain
why acetyl phosphate has not been described in human mito-
chondria so far. It is also consistent with rather rapid degradation
of synthetic acetyl phosphate in animal tissue lysates (17). In
comparison, the levels of acetate, succinate, and glutamate steadily
increased over the entire experimental time, while that of citrate
decreased. In a kinetic perspective, these time courses actually re-
semble the product and intermediate formations in a steady-state
reaction profile. Because hydrolysis of the high-energy phos-
phoester bond in acetyl phosphate can lead to acetate formation, it
might be suggested that acetyl phosphate is an intermediate of
acetate formation in mitochondria, although this may not be the
major pathway. Consistently, an acylphosphatase (EC 3.6.1.7) that
can hydrolyze an acyl phosphoester bond has been reported in the
human genome (20). The confirmation of this acetate formation
from an acetyl phosphate intermediate requires thorough biological
studies, which may also confirm a new mitochondrial metabolic
pathway. The steady decrease of citrate and increases of succinate
and glutamate seem also consistent with known metabolic path-
ways. As citrate is an early intermediate for succinate and glutamate
synthesis from pyruvate, its level may decrease steadily while those
of the two products increase in the experimental time frame. Before
this decrease, however, there must have been an initial increase in
citrate that could not be measured due to the experimental dead
time (∼5 min), as citrate was not detected at time 0 (before pyru-
vate addition; Fig. S1).
Real-Time Monitoring of Acetyl-CoA Formation Through PDH and the
Effects of p53. Another critical metabolite produced from pyru-
vate is acetyl-CoA. Despite its metabolic importance, measuring
acetyl-CoA formation through a specific pathway has been very
challenging because it is metabolized through several pathways
in different cellular compartments (i.e., mitochondria, cytosol,
and nucleus). As PDH is a mitochondrial enzyme and uses py-
ruvate as a substrate, our approach should be relevant for direct
assessment of acetyl-CoA production via the PDH-mediated
pathway. To measure acetyl-CoA production, we added CoA,
because acetyl-CoA formation through PDH requires a quanti-
tative amount of CoA (Fig. 4A). The acetyl-CoA peak was ob-
served in this condition, and UK5099 blocked its formation (Fig.
4B). These results show that our approach specifically detected
mitochondrial PDH-mediated acetyl-CoA formation, indepen-
dent of other competing pathways. Next, to evaluate the PDH
enzyme activity in live mitochondria, we measured the acetyl-CoA
formation in real time. Particularly, we used mitochondria from
HCT116 cells with p53 wild-type (WT) or knockout (KO) status
(Fig. 4C). p53 is one of the most frequently mutated genes in
Fig. 3. Real-time measurements of metabolites from live mitochondria. (A)
Time-resolved metabolite-level changes in live mitochondria. The data rep-
resent the average of six independent experiments (the overlays of all of
these datasets are shown in Fig. S2). Error bars indicate the SD. The y axis
represents femtomoles of metabolites divided by nanograms of mitochon-
drial protein. The metabolite amount was obtained in reference to the in-
ternal standard, TSP (1.45 mM), and each sample was normalized by the
amount of mitochondrial protein (about 1.5 mg) obtained with BCA assay.
Acetyl-p indicates acetyl phosphate. (B) An HSQC spectrum for a mitochon-
drial extract after 80 min incubation with 13C3-pyruvate. The red box rep-
resents the position for acetyl phosphate (1H = 2.09 ppm, 13C = 24.96 ppm).
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cancer (21) and can profoundly modulate pyruvate metabolism
(22). We observed a significantly higher rate of acetyl-CoA
formation from the mitochondria of the p53 WT cells (Fig. 4D),
suggesting that p53 up-regulates the PDH activity. The PDH
activity was also assessed through biological methods by the
levels of PDH and phosphorylated PDH (p-PDH), an inactive
form of PDH. The Western blot data showed lower levels of the
inactive p-PDH in WT cells without the changes in total PDH
(Fig. 4E), suggesting that the elevated acetyl-CoA formation
reflects the higher activity of PDH in WT cells. Our data confirm
previous suggestions that p53 modulates the PDH activity through
the regulation of PDH kinase, which phosphorylates PDH (23).
Another interesting finding from using p53 WT/KO cells is the
dependence of acetyl phosphate formation on p53 status: the
acetyl phosphate peak was observed only in the presence of WT
p53 (Fig. 4F). This suggests that acetyl phosphate may have
implications for cancer mitochondrial metabolism, given the
roles of p53 in cancer. Pyruvate metabolism to lactate in cytosol
is enhanced (Warburg effect), while its metabolism by PDH in
mitochondria is compromised in many cancer cells with p53 mu-
tations (23, 24). Because our results show higher formation of
acetyl phosphate and acetyl-CoA along with enhanced PDH
activity in p53 WT cells, the regulation of these two molecules
may be associated with p53’s tumor suppressor activity through
PDH modulation and Warburg effect suppression.
In conclusion, our in-organelle live 2D NMR metabolomics
approach, with its high sensitivity and time-resolved monitoring,
enabled the observation of previously uncharacterized acetyl
phosphate in human mitochondria. In addition, it allowed for the
measurement of mitochondrial PDH-specific production of
acetyl-CoA, as modulated by p53. The approach should allow for
detailed understanding of mitochondrial cancer metabolism, in-
dependent of competing cytosolic pathways. Recently, mitochon-
drial malfunction has been implicated in the pathophysiologies
of other diseases such as Alzheimer’s, Parkinson’s, and mus-
cular dystrophy, and therapeutic approaches targeting mitochon-
dria are being explored (25–27). Therefore, our method could also
be applied to both basic mechanisms and novel therapeutics for
those diseases.
Materials and Methods
Chemicals and Reagents. UK5099, a specific inhibitor of the mitochondrial
pyruvate carrier, was purchased from Santa Cruz Biotechnology. The stable
isotope-labeled 13C3-pyruvate (99%) and sodium 3-(trimethylsilyl)propionate
(2,2,3,3-d4) (TSP) (98% purity) were purchased from Cambridge Isotope
Laboratories. Other chemicals, including malate, ADP, NAD, ATP, acetyl-CoA,
CoA, glutamate, acetate, glutamine, citrate, and acetyl phosphate, were
obtained from Sigma-Aldrich.
Cell Lines. Both HCT116 WT and KO cells were cultured in DMEM (Biowest)
supplemented with 10% heat-inactivated FBS (Biowest) and 100 U/mL pen-
icillin-streptomycin (HyClone) at 37 °C in a 5% CO2 humidified incubator.
Mitochondrial Isolation and Sample Preparation for Live Mitochondrial NMR
Metabolomics. Mitochondria were isolated from 1 × 108 HCT116 cells using a
mitochondria isolation kit (Qiagen) according to the manufacturer’s in-
structions. The final mitochondrial pellet was washed with 1 mL of Dulbec-
co’s phosphate-buffered saline (DPBS) by centrifugation. Small aliquots of
samples were also taken for protein quantification with a bicinchoninic acid
(BCA) protein assay kit (Thermo Fisher Scientific) and Western blot analysis.
Mitochondria were resuspended in 100 μL of analysis buffer (120 mM KCl,
5 mM KH2PO4, 1 mM EGTA, and 3 mM Hepes pH 7.4) (28) and incubated for
30 min at 37 °C. Next, the mitochondrial preparation was mixed with 200 μL
of pyruvate solution (13C3-pyruvate, malate, NAD, and ADP; pH 6.8). CoA
was added as needed. The final concentrations were as follows: 0.25 mM
malate, 0.25 mM NAD, 0.1 mM ADP, 3 mM CoA, and 3 mM 13C3-pyruvate.
D2O (10%) for the lock purpose and TSP (1.45 mM) as an internal standard
were also added. The mixture was then put in a 5-mm Shigemi tube for NMR
analysis. For the treatment with UK5099, the concentration of UK5099 was
3 mM in the analysis buffer.
Mitochondrial MTT Assay. The functionality of the mitochondria during and
after the NMR experiments was tested by MTT assay. A mitochondrial
preparation was put into an NMR tube, and aliquots were taken out at 0-, 40-,
and 80-min time points. Next, 8-μL mitochondrial suspensions were seeded
on a 96-well plate containing 62 μL of NMR sample buffer (analysis buffer plus
Fig. 4. Measurement of acetyl-CoA production in live mitochondria. (A)
Conversion of 13C3-pyruvate into
13C2-acetyl-CoA by PDH. Red indicates
13C
isotopes. (B) HSQC spectra of standard acetyl-CoA (STD) (Top), mitochondrial
preparations 40 min after the addition of 13C3-pyruvate and CoA (Bottom
Left), and the same experiment with added UK5099 (Bottom Right). The red
boxes correspond to the methyl peak of acetyl-CoA (1H = 2.34 ppm, 13C =
32.76 ppm). (C) Western blot of the HCT116 WT and KO cells for p53. (D)
Time-resolved acetyl-CoA changes in live mitochondria from p53 WT (black)
and p53 KO (red) cells. The data represent the average of three independent
experiments. Error bars indicate the SD. The y axis represents femtomoles of
metabolites divided by nanograms of mitochondrial protein. (E) Western
blot (Left) for PDH, p-PDH, and β-actin. The bar charts (Right) represent the
relative amounts of the respective enzymes normalized to that of β-actin
(n = 3). A significant change is indicated as P < 0.05 by Student’s t test. The
error bars indicate the SD. (F) HSQC spectra of live mitochondrial prepara-
tions of p53 WT and KO cells taken at 30 min after the addition of 13C3-
pyruvate and CoA. The red boxes correspond to the methyl peak of acetyl
phosphate (1H = 2.09 ppm, 13C = 24.96 ppm). For B, D, and F, mitochondrial
samples corresponding to about 400 μg of mitochondrial protein were used.








pyruvate solution), 10 μL of MTT assay buffer (100 mM MgCl2, 100 mM ATP,
and 100 mM sodium succinate), and 20 μL of MTT solution (5 mg/mL). For each
time point, the suspensions were transferred into 1.5 mL tubes and harvested
by centrifugation. The formazan crystals in the suspensions were extracted
with 100 μL of dimethyl sulfoxide (DMSO) and transferred to a 96-well plate
for spectrophotometric quantitation at 595 nm using a microplate reader
(VersaMax).
Mitochondrial Respiration Measurement. To confirm the functionality of the
isolated mitochondria, respiration measurement was carried out with
MitoXpress (Luxcel Biosciences) fluorescent dye following the manufacturer’s
protocol. The procedure involves a step that blocks oxygen exchange into
the mitochondrial sample with mineral oil. The experiment was carried out
with varying concentrations of mitochondria in 96-well plates. The fluores-
cence signal was measured at 1-min intervals for 100 min on a SpectraMax
M5 microplate reader (Molecular Devices), with wavelengths of 380 nm for
excitation and 650 nm for emission.
Sample Extraction for NMR Spectroscopy and LC-MS. Metabolite extraction
was performed on isolated mitochondria from HCT116 cells. The metabolites
were extracted using methanol, followed by freeze-drying. Methanol (1 mL)
was added to the mitochondrial NMR sample (270 μL) for protein pre-
cipitation, and 6 mL of distilled water was also added for freeze-drying.
Lastly, the freeze-dried pellet was resuspended in 270 μL of buffer composed
of 2 mM Na2HPO4 and 5 mM NaH2PO4 in D2O with TSP (1.45 mM) as an
internal standard for NMR spectroscopy. After the NMR analysis, 10 μL of the
NMR sample was mixed with 10 μL of acetonitrile, and 2 μL of the mixture
was injected for LC-MS/MS analysis.
NMR Measurement. 1H and 13C HSQC NMR spectra were measured on a
600-MHz Bruker Avance spectrometer equipped with a cryogenic triple-
resonance probe (National Center for Inter-University Research Facilities,
Seoul National University). HSQC NMR spectra were acquired at 37 °C for the
required time points, with the following parameters: pulse program,
“hsqcetgpsisp2.2”; spectral widths, 80 ppm along the 13C and 12 ppm along
the 1H dimensions; and 1,024 (for proton) × 128 (for carbon) points. One
experiment took about 5 min. The decoupled HMBC spectrum was acquired
using an HMQC pulse sequence (hmqcgpqf) with the heteronuclear J cou-
pling parameter set to 7 Hz. The other parameters were the same as in a
standard HMBC experiment.
Identification and Quantification of Metabolites. The metabolites were initially
identified in reference to known pyruvate metabolic pathways and NMR
metabolite databases such as the Human Metabolome Database (29), Bio-
MagResBank (30), and SpinAssign (31). The identifications were further
confirmed by spiking experiments with standard samples. For acetyl phos-
phate, additional confirmation was obtained using HMBC NMR spectroscopy
and LC-MS. For quantification, we performed 2D integration of the me-
tabolite peaks derived from 13C3-pyruvate, as not all of the carbons can be
from pyruvate. The particular proton–carbon pairs that were used for the
peak quantifications are listed in Table S1. The levels of metabolites were
expressed as amount of metabolites (in femtomoles) obtained from peak
integrals, normalized by the amount of mitochondrial protein (in nano-
grams). The concentration of each metabolite was obtained using the in-
ternal standard (TSP, 1.45 mM) as the reference. Taking into account the
natural abundance of the TSP signal and the number of protons, the amount
of each metabolite in the total incubation volume of 270 μL was calculated.
The mitochondrial protein amount was obtained using the well-established
BCA assay procedure after dissolving the mitochondria in lysis buffer.
LC-MS/MS for Acetyl Phosphate Identification. For LC-MS/MS analysis, HPLC
was performed on an Agilent 1100 Series liquid chromatography system
(Agilent) with a ZIC-pHILIC polymeric bead, poly(ether-ether-ketone) (PEEK)-
coated column (150 × 2.1 mm, 5 μm; Merck KGaA) at 35 °C. For the mobile
phase, A and B were distilled water plus 10 mM ammonium carbonate (pH
9.0) and acetonitrile, respectively. The linear gradient was as follows: 80% B
at 0 min, 35% B at 10 min, 5% B at 12 min, 5% B at 25 min, 80% B at
25.1 min, and 80% B at 35 min, with a 0.15 mL/min flow rate. MS data were
acquired using an API 2000 mass spectrometer (AB/SCIEX) equipped with an
electrospray ionization source. In detecting acetyl phosphate, the multiple
reaction monitoring transitions of parent ion to fragment ion, 139>79 m/z
for 12C-acetyl phosphate and 141>79 m/z for 13C2-acetyl phosphate, were
monitored in a negative-ion detection mode.
Western Blot Analysis. Western blots were performed using a routine pro-
cedure with nitrocellulose membranes (Millipore). For detection, the fol-
lowing antibodies were used: rabbit polyclonal antibody against phospho-
PDHE1-α Ser293 (EMD Millipore); mouse monoclonal antibodies against p53,
PDHE1-α, HSP60, and β-actin; goat polyclonal antibodies against GAPDH;
and horseradish peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnology).
Transmission Electron Microscopy Analysis. The mitochondrial pellet isolated
from 2 × 108 cells was fixed in 1% glutaraldehyde with 100 mM phosphate
buffer for 2 h and washed with 100 mM phosphate buffer three times. After
postfixation in 1% (wt/vol) osmium tetroxide (OsO4), the sample was
dehydrated in increasing concentrations of ethanol (70%, 80%, 90%, 95%,
and 100%) and immersed in propylene oxide as a transition solvent. Next,
the sample was embedded in epon812 resin (Electron Microscopy Sciences)
and polymerized at 60 °C for 73 h. After resin-embedding, the sample was
cut into 60-nm thick sections with an ultramicrotome (Ultracut E; Reichert-
Jung), and the sections were placed onto a 200-mesh copper grid (Electron
Microscopy Sciences). The grid containing the sections was then stained in
3% uranyl acetate and lead citrate. After drying the grid, the sections were
observed with a transmission electron microscope (JEM-1011; JEOL) oper-
ating at 80 kV.
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